![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, April 07, 2014 7:49:54 PM
We had a secondary offering in Oct 2012 at $4. It's April 2014 and we're 17% below that price. Were we that overvalued to begin with? You've got companies like MNKD trading at north of $2B valuations. No revenues, no products even on the market. And here we are at $430MM, $70MM of which is cash. So $360MM for a product (Otrexup) that may very well do that number in revenues a few years from now. Plus $20MM in existing revenues. Epipen next year. QST and Pfizer OTC in 2016. QSM and more in 2017 and beyond. We're likely to be profitable by Q4 this year.
$360MM for all of that. Basically 1.5x peak revenues for Otrexup and no value for anything else.
Wow.
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM